Clinical decision limits as criteria for setting analytical performance specifications for laboratory tests.

Analytical performance specification Biological variation Clinical performance Clinically significant difference Diagnostic variation

Journal

Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422

Informations de publication

Date de publication:
01 Feb 2023
Historique:
received: 02 09 2022
revised: 17 01 2023
accepted: 18 01 2023
pubmed: 25 1 2023
medline: 22 2 2023
entrez: 24 1 2023
Statut: ppublish

Résumé

The biological (CV The sum of the CV The obtained CAAPS were 44.9% for urine albumin, 0.6% for plasma sodium, 22.9% for plasma pancreatic amylase, and 8.0% for plasma creatinine (z = 3, α = 2.5%, 1-β = 85%). For blood HbA The CAAPS models pose a new tool for assessing APS in a clinical laboratory. Their usability depends on the relevance of CD limits, required statistical power and the feasibility of repeated measurements.

Sections du résumé

BACKGROUND BACKGROUND
The biological (CV
METHODS METHODS
The sum of the CV
RESULTS RESULTS
The obtained CAAPS were 44.9% for urine albumin, 0.6% for plasma sodium, 22.9% for plasma pancreatic amylase, and 8.0% for plasma creatinine (z = 3, α = 2.5%, 1-β = 85%). For blood HbA
CONCLUSIONS CONCLUSIONS
The CAAPS models pose a new tool for assessing APS in a clinical laboratory. Their usability depends on the relevance of CD limits, required statistical power and the feasibility of repeated measurements.

Identifiants

pubmed: 36693582
pii: S0009-8981(23)00026-8
doi: 10.1016/j.cca.2023.117233
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117233

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Emmi Rotgers (E)

Department of Clinical Chemistry, University of Helsinki, and HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, FIN-00029 Helsinki, Finland.

Solveig Linko (S)

Linko Q-Solutions, FIN-00950 Helsinki, Finland.

Elvar Theodorsson (E)

Department of Biomedical and Clinical Sciences, Division of Clinical Chemistry and Pharmacology, Linkoping University, SE-58183 Linkoping, Sweden.

Timo T Kouri (TT)

Department of Clinical Chemistry, University of Helsinki, and HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, FIN-00029 Helsinki, Finland. Electronic address: timo.kouri@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH